Portfolio News
Sofinnova Industrial Biotech
DMC appoints Kelly Smith as VP R&D
Related Strategy
Industrial BiotechRelated Deal lead
Joško BobanovićRelated Company
DMC Biotechnologies15 March 2022 – Kelly Smith, Ph.D., has joined DMC Biotechnologies as VP R&D. Previously, she was head of bioprocessing and formulation development at Joyn Bio. Kelly has more than 20 years of experience building and leading research and development teams and has a Ph.D. in Environmental Engineering Science from the California Institute of Technology.
Kelly has a broad diversity of experience in both start-up and large companies, including multiple product launches from concept to commercial. She has diverse technical experience across a range of roles and functions, and experience in a variety of product and application areas.
Matt Lipscomb, Ph.D., CEO & co-founder of DMC said, “Kelly has exceptional leadership qualities with a track record of building engaged, high-trust and high-results teams. As we expand our operations at DMC, we are excited to welcome Kelly to the team.”
DMC’s technology platform addresses the key barriers that have plagued the biotech industry for decades including standardization, robustness, and predictability across scale. Addressing these challenges translates to a dramatic reduction in the time to market and the investment needed to bring products to commercialization.
DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com
About DMC
DMC is a U.S. bio-based chemical company that makes products using microbial fermentation. DMC’s proprietary technology platform simplifies the engineering of biology and makes fermentation more standardized, robust, and predictable.
For more information, visit: www.dmcbio.com
Related News
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in atraumatic sutureless peripheral nerve repair
Moon Surgical Expands Leadership Team to Accelerate Commercial Growth Across U.S. and Europe
Micropep and Corteva announce multi-year research collaboration to advance sustainable biocontrol solutions
Gradient Denervation Technologies announces acceptance into FDA’s Total Product Life Cycle Advisory Program for development of its pulmonary artery denervation system
AFYREN begins new phase of industrial strategy as first plant AFYREN NEOXY achieves continuous production